Parkinson's Drug Developers Shift Focus to Neuroinflammation as Alpha-Synuclein Strategy Stalls
核心洞察
Jefferies (搜索) analysts identify neuroinflammation as one of the most important emerging storylines in Parkinson's disease (搜索) drug development, with key milestones expected heading into 2027.
The addressable early Parkinson's population across the US and EU is projected to exceed two million patients by 2035, representing a potential disease-modifying therapy market approaching $8 billion.
BioVie's bezisterim reported positive Phase 2 topline data showing improvements in blood-based inflammatory markers and clinical outcomes, with patients having higher baseline inflammation seeing the greatest benefit.
For years, the hunt for a Parkinson's disease (搜索)-modifying drug centered on a single protein: alpha-synuclein (搜索). Clear it out, the thinking went, and you slow the disease. That bet has not paid off yet. Now, according to a new research note from Jefferies (搜索), a growing segment of the pharmaceutical industry is chasing a different culprit: inflammation in the brain itself.
The investment bank is not abandoning alpha-synuclein (搜索), but it is telling clients that neuroinflammation has become one of the field's most important storylines—one worth watching closely heading into 2027. "Despite decades of investment, no therapy has convincingly demonstrated an ability to slow neurodegeneration," analysts wrote. "With several late-stage and emerging programmes now approaching important clinical milestones, we believe the field is entering a pivotal period that could determine whether disease modification becomes a commercial reality."
The opportunity, in Jefferies (搜索)' view, is too large to ignore even with the field's track record of disappointment. Parkinson's remains one of the largest untapped opportunities in neuroscience, with the addressable early population across the US and EU expected to exceed two million patients by 2035. That represents a potential disease-modifying therapy market approaching $8 billion, the bank's analysts noted.
The Case Against Single-Pathway Approaches
Recent late-stage trial results have reinforced the argument that Parkinson's is a multi-mechanism disease. Roche and Prothena's prasinezumab, the most advanced disease-modifying antibody in Parkinson's, has missed its primary endpoint twice—though both trials hinted at slower motor decline, enough for Roche to advance the drug into Phase III. Denali (搜索)'s LRRK2 (搜索)-targeting drug BIIB122 fared worse, failing outright in broad Parkinson's patients and now being tested only in a genetically defined subgroup.
Jefferies (搜索) reads both results not as target failures but as evidence that Parkinson's is driven by multiple mechanisms simultaneously: alpha-synuclein (搜索) pathology, cellular cleanup breakdown, and neuroinflammation. Single-pathway drugs, the analysts argue, likely will not be enough on their own. "Given much of the pathological protein resides intracellularly, we believe next-generation modalities may ultimately prove better suited to targeting the underlying biology," analysts wrote.
The Inflammation-Alpha-Synuclein (搜索) Interplay
The logic behind the neuroinflammation approach is not that inflammation replaces alpha-synuclein (搜索) as a target. Rather, the two likely feed each other. Quiet the inflammation, the theory goes, and you may blunt the damage alpha-synuclein is doing at the same time. Analysts group neuroinflammatory drugs with next-generation vaccines and intracellular alpha-synuclein approaches, rather than treating them as a separate, competing bet.
Among the approaches drawing the most attention are drugs that target alpha-synuclein (搜索) inside cells, vaccine candidates, and treatments aimed at neuroinflammation. "The field is increasingly focused on next-gen modalities that could more effectively address the underlying biology of PD," the analysts wrote.
Companies Advancing the Inflammation Thesis
Several companies sit closest to the mechanism Jefferies (搜索) is highlighting. Ventyx Biosciences is developing oral inhibitors of NLRP3 (搜索), the inflammasome pathway the bank calls out by name, and is one of the more advanced pure-play programs in that space. Olatec Therapeutics (搜索), a private biotech, is chasing the same target with its drug dapansutrile.
BioVie Inc (搜索) has spent years developing bezisterim, an oral therapy that crosses into the brain and dials down inflammatory signaling through the NFκB and TNF-alpha pathways while also improving insulin sensitivity. The company recently reported topline data from its Phase 2 SUNRISE-PD trial in early Parkinson's patients, with patients showing improvements in blood-based inflammatory markers and a range of clinical outcomes compared with placebo. Notably, patients with higher baseline inflammation saw the greatest benefit.
Tiziana Life Sciences Ltd is running a smaller trial testing an intranasal antibody called foralumab in Multiple System Atrophy (搜索), a Parkinson's-related disorder with no approved disease-modifying treatment. The goal is to calm overactive brain immune cells called microglia. Early PET scans have shown drops in brain inflammation in the handful of patients treated so far.
A Field at a Turning Point
Companies targeting inflammation are riding the same wave: the idea that calming the brain's immune response could do as much for Parkinson's patients as chasing alpha-synuclein (搜索) ever did. Whether that idea holds up remains unproven, but it is exactly the kind of bet Jefferies (搜索) thinks is worth making right now, in a field it believes is finally approaching a real turning point.